Download PDF
TumorDiagnostik & Therapie 2024; 45(06): 370-375
DOI: 10.1055/a-2231-7157
Übersicht
Schwerpunkt

Behandlung des metastasierten Melanoms

Georg Lodde
,
Robin Tamara Eisenburger
,
Dirk Schadendorf
› Further Information
Also available at
    Permissions and Reprints

In Deutschland werden ca. 70% aller malignen Melanome in einem frühen Tumorstadium diagnostiziert. Dennoch versterben aufgrund der hohen Metastasierungsrate jährlich weiterhin ca. 55500 Menschen weltweit [1]. Im Folgenden werden insbesondere die Herausforderungen in der Behandlung des metastasierten Melanoms thematisiert.

Schlüsselwörter

Metastasiertes Melanom - Immuntherapie - Zielgerichtete Therapie - Zelluläre Therapie


Publication History

Article published online:
02 August 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Schadendorf D, van Akkooi ACJ, Berking C. et al. Melanoma. The Lancet 2018; 392: 971-984 DOI: 10.1016/S0140-6736(18)31559-9. (PMID: 30238891)
    CrossrefPubMedGoogle Scholar
  • 2 Wolchok JD, Chiarion-Sileni V, Gonzales R. et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. Journal of Clinical Oncology 2021; 39 (Suppl. 15) 9506-9506
    CrossrefPubMedGoogle Scholar
  • 3 Robert C, Ribas A, Schachter J. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncology 2019; 20 (09) 1239-1251
    CrossrefPubMedGoogle Scholar
  • 4 Robert C, Grob JJ, Stroyakovskiy D. et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med 2019; 381 (07) 626-636
    CrossrefPubMedGoogle Scholar
  • 5 Hodi FS, Chiarion-Sileni V, Gonzales R. et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. Journal of Clinical Oncology 2022; 40 (Suppl. 16) 9522-9522
    CrossrefPubMedGoogle Scholar
  • 6 European Medicines Agency (EMA). Opdualag. 2022 https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag
    PubMedGoogle Scholar
  • 7 Long GV, Hodi FS, Lipson EJ. et al. 1103P Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047. Annals of Oncology 2023; 34: S664-S665
    CrossrefPubMedGoogle Scholar
  • 8 Tawbi HA, Schadendorf D, Lipson EJ. et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New Engl J Med 2022; 386 (01) 24-34 DOI: 10.1056/NEJMoa2109970. (PMID: 34986285)
    CrossrefPubMedGoogle Scholar
  • 9 Lipson E.J, Dolfi S, Tang H. et al. LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047. Annals of Oncology 2023; 34: S1290-S1291
    CrossrefPubMedGoogle Scholar
  • 10 Larkin J, Chiarion-Sileni V, Gonzales R. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J of Med 2015; 373 (01) 23-34
    CrossrefPubMedGoogle Scholar
  • 11 Hassel JC, Zimmer L, Sickmann T. et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers (Basel) 2023; 15 (13) 3448 DOI: 10.3390/cancers15133448. (PMID: 37444558)
    CrossrefPubMedGoogle Scholar
  • 12 Arance A, de la Cruz-Merino L, Petrella TM. et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol 2023; 41 (01) 75-85 DOI: 10.1200/JCO.22.01989. (PMID: 36809080)
    CrossrefPubMedGoogle Scholar
  • 13 Heinzerling L, Eigentler TK, Fluck M. et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 2019; 4 (03) e000491 DOI: 10.1136/esmoopen-2019-000491. (PMID: 31231568)
    CrossrefPubMedGoogle Scholar
  • 14 Dummer R, Flaherty KT, Robert C. et al. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol 2022; 40 (36) 4178-4188 DOI: 10.1200/JCO.21.02659. (PMID: 35862871)
    CrossrefPubMedGoogle Scholar
  • 15 Robert C, Karaszewska B, Schachter J. et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2014; 372 (01) 30-39
    CrossrefPubMedGoogle Scholar
  • 16 Ugurel S, Röhmel J, Ascierto PA. et al. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition – Update 2019. Eur J Cancer 2020; 130: 126-138
    CrossrefPubMedGoogle Scholar
  • 17 Weichenthal M, Svane IM, Sekulovic LK. et al. EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition. J Clin Oncol 2022; 40 (Suppl. 16) 9540-9540 DOI: 10.1200/JCO.22.01763. (PMID: 36166727)
    CrossrefPubMedGoogle Scholar
  • 18 Atkins MB, Lee SJ, Chmielowski B. et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134. J Clin Oncol 2023; 41 (02) 186-197 DOI: 10.1200/JCO.22.01763. (PMID: 36166727)
    CrossrefPubMedGoogle Scholar
  • 19 Ascierto PA, Mandalà M, Ferrucci PF. et al. 1083MO Brain metastases and survival evaluation in the SECOMBIT trial. Annals of Oncology 2023; 34: S653
    CrossrefPubMedGoogle Scholar
  • 20 Livingstone E, Gogas H, Kandolf-Sekulovic L. et al. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial. European Journal of Cancer 2023; 190: 112941
    CrossrefPubMedGoogle Scholar
  • 21 Garbe C, Keim U, Amaral T. et al. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol 2022; 40 (32) 3741-3749
    CrossrefPubMedGoogle Scholar
  • 22 Eggermont AMM, Blank CU, Mandala M. et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer 2019; 116: 148-157 DOI: 10.1016/j.ejca.2019.05.020. (PMID: 31200321)
    CrossrefPubMedGoogle Scholar
  • 23 Eggermont AMM, Kicinski M, Blank CU. et al. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. NEJM Evidence 2022; 1 (11) EVIDoa2200214 DOI: 10.1056/EVIDoa2200214. (PMID: 38319852)
    CrossrefPubMedGoogle Scholar
  • 24 Larkin J, Del Veccio M, Mandalà M. et al. Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clin Cancer Res 2023; 29 (17) 3352-3361
    CrossrefPubMedGoogle Scholar
  • 25 Dummer R, Hauschild A, Santinami M. et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2020; 383 (12) 1139-1148 DOI: 10.1056/NEJMoa2005493. (PMID: 32877599)
    CrossrefPubMedGoogle Scholar
  • 26 Luke JJ, Rutkowski P, Queirolo P. et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. The Lancet 2022; 399: 1718-1729 DOI: 10.1016/S0140-6736(22)00562-1. (PMID: 35367007)
    CrossrefPubMedGoogle Scholar
  • 27 Long GV, Swetter SM, Menzies AM. et al. Cutaneous melanoma. Lancet 2023; 402: 485-502 DOI: 10.1016/S0140-6736(23)00821-8. (PMID: 37499671)
    CrossrefPubMedGoogle Scholar
  • 28 Lodde GC, Hassel J, Wulfken LM. et al. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study. Eur J Cancer 2023; 191: 112957 DOI: 10.1016/j.ejca.2023.112957. (PMID: 37487400)
    CrossrefPubMedGoogle Scholar
  • 29 Weichenthal M, Schadendorf D, Bastholt L. et al. 1104P Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study. Annals of Oncology 2023; 34: S665-S666
    CrossrefPubMedGoogle Scholar
  • 30 Cagney DN, Martin AM, Catalano PJ. et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 2017; 19 (11) 1511-1521
    CrossrefPubMedGoogle Scholar
  • 31 Davies MA, Saiag P, Robert C. et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. The Lancet Oncology 2017; 18 (07) 863-873
    CrossrefPubMedGoogle Scholar
  • 32 Tawbi HA, Forsyth PA, Algazi A. et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 2018; 379 (08) 722-730 DOI: 10.1056/NEJMoa1805453. (PMID: 30134131)
    CrossrefPubMedGoogle Scholar
  • 33 Di Giacomo AM, Chiaroni-Sileni V, Del Vecchio. et al. 1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. Annals of Oncology 2023; 34: S653-S654
    CrossrefPubMedGoogle Scholar
  • 34 Glitza Oliva IC, Ferguson SD, Bassett Jr R. et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nature Medicine 2023; 29 (04) 898-905
    CrossrefPubMedGoogle Scholar
  • 35 Rohaan MW, Borch TH, van den Berg J. et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med 2022; 387 (23) 2113-2125 DOI: 10.1056/NEJMoa2210233. (PMID: 36477031)
    CrossrefPubMedGoogle Scholar
  • 36 Borgers JSW, Lenkala D, McCarthy B. et al. 1017O NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma. Annals of Oncology 2023; 34: S619 DOI: 10.1016/j.annonc.2023.11.013. (PMID: 38048850)
    CrossrefPubMedGoogle Scholar